Newly Diagnosed With Mantle Cell Lymphoma

If you search for mantle cell lymphoma you will find frightening descriptions and reassuring ones. Both can be accurate, because NCI describes two clinical subtypes.

About 20 percent of people have the indolent form, often called non-nodal leukemic mantle cell lymphoma. It sits in the blood, marrow, and spleen more than in swollen nodes. NCI reports a median survival above 15 years for this group, and says many can put off treatment at first and be watched.

The rest have the nodal form, which behaves more aggressively. A third pattern, isolated polyps in the bowel, also runs an indolent course.

Most people, whichever type, have stage III or IV disease when it is found. In mantle cell lymphoma that is normal rather than alarming. NCI describes the disease as highly responsive to treatment, though not curable in most cases.

Mantle cell lymphoma comes from B cells in the mantle region of a lymph node. The usual pattern is CD5-positive, CD20-positive, cyclin D1-positive, CD10-negative, and CD23-negative or low.

More than 95 percent of cases carry the classic fusion between the IGH and CCND1 genes, usually from a swap between chromosomes 11 and 14. That is what drives the excess cyclin D1.

Four further results sort you into a group, so ask for each by name.

• SOX11: low or negative, under 10 percent, points to the indolent form. High, at 10 percent or more, points to the nodal form.
• Ki-67: 30 percent or more marks a faster disease.
• Appearance: a blastoid or pleomorphic look under the microscope marks a harder course.
• TP53: a change here matters most of all, because NCI says standard chemoimmunotherapy is particularly ineffective when TP53 is altered.

Median survival with a blastoid or pleomorphic appearance, a high Ki-67, or a TP53 change is 4 to 7 years. NCI also notes that any mantle cell lymphoma can later shift into that harder form.

For the indolent form, NCI describes watchful waiting for people who have no symptoms, only a small amount of enlarged nodes, no significant spleen enlargement, and normal blood counts.

There is a reason beyond the biology. Most people with mantle cell lymphoma are over 60, and the disease is not treated with the aim of cure. So the physical and financial cost of treatment has to be weighed against what it buys.

When treatment is needed for indolent disease, a gentler start is preferred. NCI describes beginning with rituximab alone and adding a BTK inhibitor if the response is not good enough after 4 to 8 weeks.

Through the 2010s the standard for fit younger people was intensive: R-CHOP alternating with R-DHAP, then an autologous stem cell transplant, then rituximab maintenance. For older people it was bendamustine with rituximab.

That has shifted. NCI says randomised trials using BTK inhibitors now give sufficient evidence to avoid autologous stem cell transplant and high-dose cytarabine in most people. Maintenance rituximab for at least 2 to 3 years remains standard after first-line treatment.

The BTK inhibitors are worth checking carefully, because their approvals differ. Acalabrutinib combined with bendamustine and rituximab is FDA-labelled for previously untreated mantle cell lymphoma in people who cannot have an autologous transplant. Zanubrutinib is labelled only after at least one prior therapy, under an accelerated approval based on response rate. Ibrutinib no longer lists any mantle cell indication on its FDA label.

Some earlier trial comparisons still shape choices. Bendamustine with rituximab gave a median progression-free survival of 35 months against 22 months for R-CHOP, with no difference in overall survival, and it is easier to tolerate.

This disease turns up in places a lymph node scan will not show. NCI lists the lymph nodes, spleen, and bone marrow, and adds that it sometimes appears as polyps in the gut, especially the colon.

Staging is usually done with PET-CT. Colonoscopy, a bone marrow biopsy, or a lumbar puncture may be added in selected cases. If one of these is proposed, ask what result would change the plan.

One thing you may be offered but do not need outside a trial is measurable residual disease testing. NCI says it has not been shown to guide treatment decisions here.

• Call 911 or go to an emergency department if you pass black or bloody stools, or the fullness under your left ribs turns into sudden severe pain after a knock or a fall. An enlarged spleen can bleed.
• Telephone your lymphoma team the same hour, day or night, if you run a temperature of 100.4°F (38°C) or higher, or start shaking with chills, and you are on or recently finished chemoimmunotherapy. CDC treats fever during that kind of treatment as a medical emergency, because your white cells may be too low to hold an infection back. If you cannot get through, go to an emergency department and tell them what treatment you are on.
• Call your care team the same day if the same temperature or chills turn up while you are on watchful waiting and have had no chemotherapy. Being untreated does not make an infection safe to sit on, but it does mean a phone call is the right first step.
• Call your care team within a day or two if a node swells noticeably over a few weeks, night sweats soak your bedding, weight falls without you trying, or bruising, breathlessness or flattening fatigue is new.

Mantle Cell Lymphoma, What Does Flow Cytometry Mean?, Transplant vs CAR T-Cell Therapy, and Lymphoma Treatment by Stage and Type.

• https://www.cancer.gov/types/lymphoma/hp/mantle-cell-lymphoma-treatment
• https://www.cdc.gov/cancer-preventing-infections/patients/fever.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1409184-3267-4d8c-8f17-4e01f69828b1
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44